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Background: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of US cancer 
related deaths. This study assessed the oncologic benefit of a neoadjuvant chemotherapy (NAC) 
treatment strategy for patients with clinical Stage I/II PDAC. 
Methods: Patients with biopsy confirmed PDAC and clinical Stage I/II disease were treated with 
a protocol of NAC. The primary study endpoint was median overall survival (OS). Kaplan-Meier 
survival curves were compared using the log-rank test. 
Results: 56 patients met inclusion criteria. Of these, 21 patients (38%) had Stage I disease and 35 
(62%) had Stage II disease. The median OS for the entire study population was 18.7 months. A 
total of 22 (39%) patients were managed with NAC+S; 34 (61%) received NAC alone. Median 
OS and 2-year survival rates were greater in those completing NAC+S compared to NAC alone 
(median OS 28.8 months vs. 17.3 months: p=0.05; 2-year OS: 55% vs 21%: p=0.01) . 
Interestingly, patients managed with NAC who were not candidates for surgical resection after 
restaging demonstrated a survival advantage (17.3 months) compared to what was previously 
reported in historical controls. 
Conclusion: NAC+S provided a significant 11.5 month improvement in median OS compared to 
treatment with NAC alone. Modern NAC may contribute a significant oncologic benefit in the 
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According to the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results 
(SEER) Program, pancreatic cancer represents only 3.2% of all incident cancer cases in the 
United States; however, it is now the 3rd leading cause of cancer-related deaths.1 Unlike most 
solid-organ tumors, the prognosis associated with pancreatic cancer has not changed much over 
the past 30 years. Despite improvements in diagnostic and therapeutic interventions, 5-year 
survival rates remain dismal at approximately 8%.1 This can in large part be attributed to the 
typically advanced stage at which pancreatic cancer is diagnosed. Only 10% of cases are 
diagnosed early in the disease progression, when disease is confined to the primary site.1 Even 
then, 5-year survival rates are approximately 30%.1 Greater than 50% of cases have already 
metastasized at the time of initial diagnosis, and are accompanied by a 5-year survival rate of 
less than 3%1. Historically, early stage pancreatic cancer has been managed with upfront surgery 
followed by adjuvant chemotherapy and/or radiation, however, the limitations of adjuvant 
therapy have now been well described. A major area of interest to potentially improve survival 










CHAPTER I: INTRODUCTION 
Pancreatic ductal adenocarcinoma (PDAC) is presently the third leading cause of cancer related 
mortality in the United States with an estimated 44,000 deaths due to this disease in 2018.1 Since 
most cases of PDAC are diagnosed at an advanced stage, overall 5-year survival remains poor at 
8%.1 Only 10-15% of patients are considered to be surgically resectable as defined by tumor 
size, location, and vascular involvement. As surgical resection represents the only potential for 
cure, even in this small subset of eligible patients, the 5-year overall survival remains poor at less 
than 20%.2,3  
 
Regardless of the initial clinical and radiographic features, PDAC is largely regarded as a 
systemic disease at the time of diagnosis.4,5 Between 20-30% of patients who are treated with 
surgery at high-volume centers do not receive the intended adjuvant chemotherapy due to a 
combination of postoperative morbidity, patient refusal, and early disease recurrence.6-8 This has 
led to increasing support for neoadjuvant therapies in the management of patients with PDAC.9-11 
Theoretical additional benefits of neoadjuvant chemotherapy (NAC) include (1) delivery of 
chemotherapy to well-oxygenated tissues which maximizes tumor infiltration thus yielding 
higher efficacy; (2) improved rates of chemotherapy tolerance by avoiding the setbacks caused 
by extended postoperative recovery and operative complications; (3) reduced tumor volume 
resulting in possible downstaging and increased rates of R0 resections; (4) reduction in overall 
disease burden and the odds of locoregional recurrence; and (5) an opportunity to observe and 




tumor biology.12 Retrospective studies have demonstrated this treatment approach to be feasible, 
is associated with an increased percentage of patients receiving all intended therapy, and may 
provide some oncologic benefit as it relates to margin clearance and long-term patient survival.13  
 
In 2012, our institution adopted a protocol incorporating NAC prior to performing a potentially 
curative resection in patients with Stage I and II PDAC (Supplemental Figure 1). The aims of 
this observational study were to describe the overall survival of patients with Stage I/II PDAC 
who were managed with NAC and to assess if there is any added benefit of potentially curative 
















CHAPTER II: METHODS  
Data Sources 
A retrospective review of a prospectively-maintained pancreatic cancer database was conducted 
for patients who had a biopsy confirmed diagnosis of clinical stage I/II PDAC from July 1, 2012 
to July 31, 2016. Sociodemographic characteristics, chronic conditions, operative characteristics, 




A multidisciplinary tumor board guided the evaluation, treatment, and follow-up of all patients. 
Standardized definitions and the American Joint Committee on Cancer (AJCC) 7th edition 
staging system were used in the establishment of our institutional protocol which directed all 
patients with clinical stage I/II PDAC undergo NAC (Figure 1). Patients received a uniform 25% 
dose reduction of standard FOLFIRINOX therapy every two weeks (oxaliplatin 85 mg/m2, 
irinotecan 180 mg/m2, leucovorin 400 mg/m2 followed by bolus fluorouracil 400 mg/m2 on day 
1, then fluorouracil 2,400 mg/m2 as a 46-hour continuous infusion) or standard dose 
gemcitabine-nab-paclitaxel (nab-paclitaxel 125 mg/m2 followed by gemcitabine 1000 mg/m2 
administered on days one, eight, and fifteen) every four weeks. Potentially curative surgery was 
initially planned for all patients following completion of NAC and restaging, however, if found 
to have evidence of disease progression to locally unresectable or distant disease, or exacerbation 




radiation was selectively administered if deemed necessary for local control prior to surgery. For 
the purposes of data analysis, patients were categorized into two treatment groups; those who 
completed NAC followed by a potentially curative resection and those who completed NAC and 




Descriptive statistics were calculated for the entire cohort and compared between study groups 
using chi-square tests for categorical variables, and student’s t-tests and Wilcoxon rank-sum tests 
for continuous variables. Median OS was the primary study endpoint, which was defined as the 
time period from diagnosis of PDAC to death. OS was examined using the Kaplan-Meier (KM) 
method. The significance of NAC and potentially curative resection on survival were assessed 
using the log-rank test. For all analyses, a p-value ≤ 0.05 was considered the cut-off point for 
statistical significance. All analyses were performed using STATA software (version 15.1; 










CHAPTER III: RESULTS 
Study Population 
Eighty-eight patients with biopsy-confirmed Stage I/II PDAC were evaluated during the study 
period. Fifty six patients (63%) were offered and completed NAC. Of the 32 (37%) patients not 
treated with NAC, 15 (17%) patients were excluded due to poor Eastern Cooperative Oncology 
Group (ECOG) performance status, six (7%) patients refused treatment and elected best 
supportive care, five (6%) patients were lost to follow-up after their initial diagnosis, five (6%) 
patients sought immediate surgical resection at an outside institution, and one (1%) patient died 
from other causes.  
 
Baseline Characteristics 
Among the 56 patients who completed NAC, 21 (38%) presented with clinical stage I disease 
and 35 (62%) with clinical stage II disease. Baseline ECOG scores were higher for patients 
completing NAC alone (p=0.01). There was no difference in age, gender, or any other 
preoperative demographic variables or comorbidities (Table 1). Median follow-up time for the 
entire cohort was 18.7 months. 
 
Neoadjuvant Chemotherapy  
Eleven patients (20%) received FOLFIRINOX, 42 patients (75%) received gemcitabine-nab-
paclitaxel, and 3 patients (5%) were switched from FOLFIRINOX to gemcitabine-nab-paclitaxel 




resectable tumor on restaging. No difference in chemotherapy regimens was identified between 
groups (p=0.89). All patients completed their intended course of NAC. 
 
Restaging and Neoadjuvant Radiation Therapy 
After completing NAC and restaging, 16 patients (29%) were found to have progression of 
disease or exacerbation of their medical comorbidities, rendering them unfit for surgical 
resection (Figure 2). Of the remaining 40 patients (71%), 23 were considered candidates for 
potentially curative surgery while 17 were treated with neoadjuvant radiation therapy, with no 
difference between groups (p=0.44). Following radiation, an additional nine patients were found 
to be candidates for resection, thus resulting in 32 patients (57%) ultimately being offered 
potentially curative surgery. Of those, four patients refused and opted for no additional treatment.  
 
Operation 
Potentially curative resection was pursued in 28 patients (50%). During surgery, six patients 
were found to have locally advanced or distant metastatic disease, thus leading to abortion of the 
surgical procedure. For the purposes of analysis, these six patients were included in the NAC 
alone group. Ultimately, 22 patients (39%) underwent potentially curative resection with 
pancreaticoduodenectomy (n=16) or distal pancreatectomy (n=6). Of these, 19 (86%) patients 
had microscopic margin negative (R0) resections; there were no R2 resections. Seven (32%) vein 





Oncologic Outcomes  
Median OS for the entire study population was 18.7 months. There was no difference in 1-year 
survival between the NAC+S and NAC groups (86% vs 68%; p=0.11; Fig. 3), however, 2-year 
survival was significantly increased for the NAC+S group (55% vs 21%; p=0.01; Fig. 4). For 
patients who were treated with NAC+S, overall survival was greatly increased with a reported 
median OS of 28.8 months compared to 17.3 months for those who received NAC alone 
(p=0.05; Fig. 5). Comparing patients by AJCC disease stage, there were no significant 
differences in median OS (p=0.18). Similarly, while neoadjuvant radiation facilitated surgical 
















CHAPTER IV: DISCUSSION 
In our single institution experience evaluating the role of NAC in the management of patients 
with clinical stage I/II PDAC, patients who underwent potentially curative surgery after NAC 
achieved an 11.5 month improvement in survival compared to those who underwent NAC alone. 
Patients who completed NAC but were not candidates for resection demonstrated a significantly 
improved survival compared to historical controls in prior reports. 
 
Survival, Epidemiology, and End Results (SEER) data from 1992-2002 suggest that 
approximately one third of patients have clinically resectable or borderline resectable PDAC at 
diagnosis.14 Despite the initially favorable findings in this subset of patients, only 33% 
underwent potentially curative resection.14 Reasons for this failure to progress to resection are 
not captured in large database studies. In our study using a NAC approach, we demonstrated a 
similar estimate as 39% of patients with clinical Stage I/II PDAC ultimately progressed through 
treatment and received a resection. While early upfront surgery has traditionally been considered 
the standard of care, our data suggests the administration of NAC does not have a  negative 
impact on the ability to proceed to surgical resection. Additionally, all patients in our study 
completed their intended NAC course, suggesting that even with modern day therapies, rates of 
completion of intended therapy are significantly higher than demonstrated with adjuvant 





Modern day systemic chemotherapy regimens, notably FOLFIRINOX and gemcitabine-nab-
paclitaxel, initially showed efficacy in patients with metastatic pancreatic cancer.15,16 
Increasingly, these regimens have been incorporated into protocols for patients with early stage 
PDAC. In our institutional experience, application of these regimens in the neoadjuvant setting 
was associated with a  median OS of 18.7 months for the study population, which is consistent 
with reports in the current literature, including a recent meta-analysis which noted a median OS 
of 18.8 months after neoadjuvant treatment for resectable or borderline resectable PDAC.17 
Evaluating only the patients who completed NAC and subsequently underwent resection, our 
study finds a median OS of 28.8 months. Again, our results are consistent with recent studies 
which reported an increased median OS in this select group of 26.1 months.17  
 
There is a paucity of data evaluating the survival of those with resectable or borderline resectable 
disease who complete NAC but who do not progress to completed potentially curative resection. 
Historically, this group of patients has done poorly with a median OS around 7-8 months.7,18 
Interestingly, the current study demonstrated a median OS of 17.3 months in this group of 
patients, which appears greater than previous reports on the topic.7,18 Understanding the 
limitation that we are comparing results to external historical controls, the survival difference is 
notable and may still be very meaningful. As all patients in this group completed the intended 
course of chemotherapy, it is possible that NAC has impacts on tumor biology that contribute to 




While one needs to be appropriately cautious in comparing our results with the findings from  
prior published  reports, the survival difference is notable and improvements in survival with 
modern day NAC alone may be meaningful. Since all patients completed the intended course of 
chemotherapy, it is possible that NAC favorably impacts tumor biology which contributed to the 
observed improvement in OS. 
 
Most striking in the current data set is the significant improvement in median and 2 year survival 
in patients who underwent potentially curative surgery following NAC, compared to those who 
received NAC alone. Early Phase II trials demonstrated a significant improvement in survival, 
with an added benefit afforded by resection, using preoperative gemcitabine-based 
chemoradiation therapies.11 More recent studies confirmed the findings in resectable patients, but 
the data was heavily influenced by gemcitabine-based regimens.18 A recent Phase II trial by 
Murphy et al demonstrated that incorporation of a FOLFIRONOX-based neoadjuvant approach 
with individualized radiation for patients with borderline resectable PDAC may yield similar 
benefits in survival, again with added benefit afforded by potentially curative surgery.19 With 
75% of the study population receiving gemcitabine-nab-paclitaxel, the current study is the first to 
suggest that modern day regimens including gemcitabine-nab-paclitaxel—in addition to 
FOLFIRNOX—may confer a similar oncologic benefit in patients with resectable disease at 
diagnosis. While there are limited phase II studies and no phase III clinical trials to guide 
definitive decisions regarding the utility and application of NAC, several trials are ongoing 




pancreatic cancer.20-22 Certainly, the current data suggests the need to evaluate the role of modern 
day regimens in the resectable, as well as borderline resectable, populations.11,18,19 
 
Study Strengths and Limitations  
This observational study reports our four year institutional experience in managing patients with 
biopsy proven stage I/II PDAC using a NAC based approach. The study has limitations inherent 
to single-institution, retrospective review, including those related to selection bias and an 
inability to prove causality. Comparison of our data to historical series is limited given the 
heterogeneity of study populations and lack of consistency in anatomic definitions. The small 
sample size of the study prevented the ability to perform Cox regression analyses or advanced 














CHAPTER V: CONCLUSIONS 
Management strategies involving NAC with the intent for potentially curative surgery may offer 
patients with resectable, stage I/II PDAC improvements in survival even in the absence of 
resection. While patients who were able to complete all components of intended therapy 
experienced higher survival rates, patients who completed NAC may achieve even greater 
benefits on long-term survival relative to historical controls. Certainly, however, if surgery can 
be employed, it may confer an additional one year of improvement in survival and may be done 
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Table 1. Baseline characteristics of the study  
 
 
*All values recorded as (n,%) unless otherwise specified  
α: Mean (Standard deviation) 
BMI: Body mass index, ECOG: Eastern Cooperative Oncology Group, COPD: Chronic 












P value  
Age at Diagnosis (years) α   65 (10) 69 (9) 0.08 
Male  11 (50) 12 (35) 0.28 
Race    
        White 22 (100) 30 (91)  
        Black 0 (0) 1 (3)  
        Hispanic 0 (0) 2 (6)  
BMI (kg/m2) α 26 (6) 24 (6) 0.22 
ECOGα 0.1 (0.4) 0.7 (0.9) 0.01 
Initial CA19-9 α 173 (224) 600 (1927) 0.32 
Restaging CA19-9 α 470 (1306) 1465 (1948) 0.07 
AJCC Clinical Stage    0.67 
     Stage I 9 (41) 12 (35)  
     Stage II 13 (59) 22 (65)  
Diabetes 9 (41) 15 (45) 0.74 
Renal Disease 4 (18) 4 (12) 0.53 
Heart Disease 3 (14) 9 (27) 0.23 
Hypertension 10 (45) 18 (55) 0.51 
Current/Previous Smoker 12 (55) 22 (65) 0.45 
COPD 1 (5) 2 (6) 0.81 
Neoadjuvant Chemotherapy    0.89 
        FOLFIRINOX 5 (23) 6 (18)  
        Gemcitabine-nab-paclitaxel 16 (73) 26 (76)  
        Switch  1 (4) 2 (6)  
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*NAC: Neoadjuvant Chemotherapy 
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Figure 3: Kaplan Meier Analysis of 1-Year Survival for Stage I and II PDAC According to 
















Figure 4: Kaplan Meier Analysis of 1-Year Survival for Stage I and II PDAC According to 
















Figure 5: Kaplan Meier Analysis of Overall Survival for Stage I and II PDAC According to 


















Supplemental Figure 1: Pancreatic Cancer Stage IA, IB, IIA, IIB 
Copyright ID: CDR687928, CDR687932, CDR742418 
Terese Winslow LLC, Medical Illustration 
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